Findings

What do systematic reviews say?

14 questions · 14 findings · 3 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 3 · 21.4%GRADE not reported 0 · 0%Very low 4 · 28.6%Low 7 · 50%Moderate 0 · 0%High 0 · 0%

Closest answers

The findings closest to your search, judged one by one by TypeSafe's Jev model.

Direct match · question page
- Comparison 3: MAOIs vs placebo · Treatment efficacy ‐ treatment response, as measured by the Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)
  Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found
Direct match · question page
- Comparison 7: MAOIs vs placebo · Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score
  Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  4 studies · 218 participants
  Very low
Direct match · question page
- MAOIs vs placebo · Pain (VAS) VAS from: 0 to 10
  Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 121 participants
  Low
Direct match · question page
- Comparison 7: MAOIs vs placebo · Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale
  Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 51 participants
  Very low
Direct match · question page
- Comparison 7: MAOIs vs placebo · Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase)
  Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
  RR 2.36 [1.48, 3.75]
  4 studies · 235 participants
  Low

MAOIs vs placebo

Pain (VAS) VAS from: 0 to 10 · patients with fibromyalgia

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 121 participants
Low

MAOIs vs placebo

Tender points Tender point score and number of tender points · patients with fibromyalgia

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 121 participants
Low

MAOIs vs placebo

Global assessment (by patient) VAS from: 0 to 10 · patients with fibromyalgia

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 121 participants
Low

MAOIs vs placebo

Physical function · patients with fibromyalgia

The review found no eligible studies for this question.

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MAOIs vs placebo

Withdrawals due to adverse events · patients with fibromyalgia

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 149 participants
Low

MAOIs vs placebo

Nausea and vomiting · patients with fibromyalgia

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
1 study · 89 participants
Low

MAOIs vs placebo

Sleep disturbance (adverse event) · patients with fibromyalgia

The review found no eligible studies for this question.

1 finding from 1 review

Monoamine oxidase inhibitors (MAOIs) for fibromyalgia syndrome 2012 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MAOIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults (aged 18‐85)

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

MAOIs vs placebo

Dropouts due to adverse events · adults (aged 18‐85)

Comparison 3: MAOIs showed no clear difference in treatment tolerability, as measured by Dropouts due to adverse… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for post traumatic stress disorder (PTSD) 2022 · Cochrane Headline outcomes only
RR 1.14 [0.9, 1.43]
1 study · 37 participants
Low

MAOIs vs placebo

Global Impressions scale change item (CGI‐I or similar): no. of responders (acute phase) · adults with SAnD

Comparison 7: MAOIs may leads to higher global Impressions scale change item (CGI‐I or similar): no. of… compared with placebo (low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 2.36 [1.48, 3.75]
4 studies · 235 participants
Low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS total score · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 218 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS avoidance subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Reduction of of anxiety symptoms ‐ Clinician‐rated: LSAS fear subscale · adults with SAnD

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
no estimate extracted
1 study · 51 participants
Very low

MAOIs vs placebo

Clinical Global Impressions scale change item (CGI‐I): no. of responders (long term) Post‐treatment: 1‐4 months · adults with SAnD

It is very uncertain whether comparison 7: MAOIs changes clinical Global Impressions scale change item (CGI‐I):no. of… compared with placebo (very low certainty).

1 finding from 1 review

Pharmacotherapy for social anxiety disorder (SAnD) 2017 · Cochrane Headline outcomes only
RR 1.84 [1.02, 3.33]
2 studies · 113 participants
Very low